Escitalopram-induced liver injury:A case report and review of literature

• 作者: Alex Yu Sen Soh Christl Suet Kwan Yong Qin Xiang Ng Wayren Loke Wee Song Yeo
• 来源期刊: 世界肝病学杂志:英文版(电子版)
• 学科: 医学
• 关键词: DEPRESSION ANTIDEPRESSANT ESCITALOPRAM LIVER INJURY DRUG-INDUCED Druginduced LIVER INJURY
• 年，卷（期）: 2019,（10）
• 页码范围: 719-724
• 页数: 6页
• 分类号: R

摘要

BACKGROUND Depression is a growing public health problem that affects over 350 million people globally and accounts for approximately 7.5%of healthy years lost due to disability.Escitalopram,one of the first-line medications for the treatment of depression,is a selective serotonin reuptake inhibitor and one of the most commonly prescribed antidepressant medications worldwide.Although thought to be generally safe and with minimal drug-drug interactions,we herein present an unusual case of cholestatic liver injury,likely secondary to escitalopram initiation.CASE SUMMARY A 56-year-old Chinese lady presented with fever and cholestatic liver injury two weeks after initiation of escitalopram for the treatment of psychotic depression.Physical examination was unremarkable.Further investigations,including a computed tomography scan of the abdomen and pelvis and tests for hepatitis A,B and C and for autoimmune liver disease were unyielding.Hence,a diagnosis of escitalopram-induced liver injury was made.Upon stopping escitalopram,repeat liver function tests showed downtrending liver enzymes with eventual normalization of serum aspartate aminotransferase and alanine aminotransferase one-week post-discharge.CONCLUSION Clinicians should be aware of the possibility of escitalopram-induced liver injury when initiating depressed patients on antidepressant treatment.This requires extra vigilance as most patients may remain asymptomatic.Measurement of liver function tests could be considered after initiation of antidepressant treatment,especially in patients with pre-existing liver disease.